INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Profound Medical Corp and its officers or directors [1] Group 1: Financial Disclosure - On March 7, 2025, Profound disclosed an error that overstated revenue by $472,000 in Q1 2024, leading to the conclusion that its quarterly reports for the first three quarters of 2024 should no longer be relied upon [3] - Profound intends to file restated interim financial statements as soon as practicable following the identification of the error [3] Group 2: Market Reaction - Following the news of the revenue overstatement, Profound's stock price fell by $0.43 per share, or 5.9%, closing at $6.86 per share on March 7, 2025 [4]